Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Inclusion Criteria

• •Patient 18 years or older with a diagnosis of non-Hodgkin Lymphoma or chronic lymphocytic leukemia (NHL or CLL) and one of the following:
• •* Progression of NHL following at least 2 prior chemotherapy regimens, (must contain rituximab for all NHL and fludarabine for follicular NHL) defined as:
• •* failure to achieve partial remission (PR) with the last chemotherapy
• •* disease progression within 6 months following last chemotherapy
• •* Progression of CLL/SLL (small lymphocytic lymphoma) following at least 2 prior chemotherapy regimens (containing purine analogs ) in stage Rai III or IV or symptomatic disease.
• •* Relapsed NHL or CLL following stem cell transplantation for whom the option of donor lymphocyte infusion is not available or clinically indicated (e.g. recipients of autologous or umbilical cord blood \[UCB\] transplants).
• •Available related HLA-haploidentical (human leukocyte antigen) natural killer (NK) cell adult donor by at least Class I serologic typing
• •Karnofsky performance status \> 60%
• •Measurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)
• •Have acceptable organ function as defined within 28 days of enrollment:
• •* Hematologic: platelets ≥ 80,000 x 10\^9/L; hemoglobin ≥ 9g/dL, unsupported by transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10\^9/L, unsupported by granulocyte-colony stimulating factor or granulocyte-macrophage colony-stimulating factor (G-CSF or GM-CS)F for 10 days or Neulasta for 21 days - the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by lymphoma who are otherwise eligible
• •* Renal: glomerular filtration rate (GFR) \> 50 ml/min
• •* Hepatic: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \< 3 x upper limit of normal and total bilirubin \<3 mg/dl
• •* Pulmonary function: \>50% corrected carbon monoxide diffusing capacity (DLCO) and Forced Expiratory Volume in the first second (FEV1)
• •* Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection fraction \>40%
• •Off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0
• •Women of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment.
• •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.